Document is current
Any future updates will be listed below
-
Authors
Reinders, Margot T. M. https://orcid.org/0000-0002-0501-9427
Braat, Arthur J. A. T. https://orcid.org/0000-0002-8824-8697
van Erpecum, Karel J. https://orcid.org/0000-0003-4034-5444
de Bruijne, Joep
Bruijnen, Rutger C. G. https://orcid.org/0000-0002-5167-4027
Sprengers, Dave https://orcid.org/0000-0003-4280-4210
de Man, Rob
Vegt, Erik https://orcid.org/0000-0001-7456-2258
IJzermans, Jan N. M. https://orcid.org/0000-0003-3558-1039
Elias, Sjoerd G. https://orcid.org/0000-0003-3903-4024
Lam, Marnix G. E. H. https://orcid.org/0000-0002-4902-9790
Smits, Maarten L. J. https://orcid.org/0000-0003-4735-655X
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (P10307)
- License Information
-
More Information
Article History
Received: 7 July 2024
Accepted: 29 September 2024
First Online: 29 October 2024
Declarations
:
: This clinical study was approved by the Medical Ethics Committee of University Medical Centre Utrecht and Erasmus Medical Centre and by the institutional radiation protection committee. Furthermore, this study was performed in concordance with Good Clinical Practice and the declaration of Helsinki.
: All participants provided written, informed consent before undergoing any study-specific activity.
: Margot Reinders-Hut is currently employed by Genmab B.V., acted as a speaker for Boston Scientific. Marnix Lam acts as a consultant for Terumo, Quirem Medical and Boston Scientific, receives research support from Terumo, Quirem Medical and Boston Scientific. Maarten Smits and Arthur Braat are consultants for Terumo. The department of Radiology and Nuclear Medicine of the University Medical Centre Utrecht receives royalty payments from Quirem Medical.
